| KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy ÁK Ghimessy, Á Gellert, E Schlegl, B Hegedus, E Raso, T Barbai, J Timar, ... Cancers 11 (10), 1514, 2019 | 26 | 2019 |
| Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer British Journal of Cancer, 2023 | 11 | 2023 |
| Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC N Gémes, JÁ Balog, P Neuperger, E Schlegl, I Barta, J Fillinger, B Antus, ... Frontiers in Immunology 14, 1297577, 2023 | 4 | 2023 |
| The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation P Radeczky, Z Megyesfalvi, V Laszlo, J Fillinger, J Moldvay, E Raso, ... Translational Lung Cancer Research 10 (2), 675, 2021 | 3 | 2021 |
| Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas E Papp, A Steib, EMM Abdelwahab, J Meggyes-Rapp, L Jakab, G Smuk, ... BMJ Open Respiratory Research 7 (1), e000505, 2020 | 2 | 2020 |
| Predictive relevance of KRAS mutational status in bone metastatic lung adenocarcinoma treated with bisphosphonate therapy P Radeczky, Z Megyesfalvi, J Fillinger, V László, E Rásó, J Moldvay, ... Magyar Onkologia 65 (2), 103-111, 2021 | | 2021 |
| A KRAS-mutációs státusz prediktív szerepe biszfoszfonáttal kezelt, csontáttétet képző tüdő-adenokarcinómában P Radeczky, Z Megyesfalvi, J Fillinger, V László, E Rásó, J Moldvay, ... MAGYAR ONKOLÓGIA 65, 103-111, 2021 | | 2021 |
Áron Kristóf GhimessyOrszágos Onkológiai IntézetVerified email at oncol.hu
